The antifungal drug prescribed for more than just fungal infections is ketoconazole, a medication originally developed to fight yeast and mold that has quietly become a workhorse in endocrinology and oncology clinics. Ketoconazole inhibits not only the fungal enzymes it was designed to target but also a range of human steroidogenesis enzymes, which means it can suppress cortisol production in Cushing’s syndrome and block androgen activity in prostate cancer. It is approved in Europe specifically for treating Cushing’s syndrome and is used off-label for the same purpose in the United States, where it is recommended as a second-line treatment after transsphenoidal surgery. Its inclusion on the WHO Essential Medicines List with a specific review for Cushing syndrome use reflects just how far this drug has traveled from its antifungal origins.
Ketoconazole is not alone in this second career. Itraconazole, another antifungal in the azole class, has emerged in drug repurposing research as a potential anticancer agent, with clinical trials exploring its use against prostate cancer, basal cell carcinoma, non-small cell lung cancer, and several other malignancies. A January 2025 study published in Frontiers in Pharmacology even found that itraconazole promotes melanoma cell death by disrupting a key signaling pathway. This article examines how these two antifungal medications work beyond their original purpose, what the clinical evidence actually shows, and what patients and caregivers should understand about the limitations and risks of using these drugs off-label.
Table of Contents
- Why Are Antifungal Drugs Prescribed for Conditions Beyond Fungal Infections?
- Ketoconazole and Cushing’s Syndrome — What the Evidence Shows
- Itraconazole’s Emerging Role in Cancer Treatment
- Comparing Ketoconazole and Itraconazole for Off-Label Use
- Risks, Drug Interactions, and Why Off-Label Use Demands Caution
- Ketoconazole Shampoo and Hair Loss — A Quieter Off-Label Use
- What Drug Repurposing Means for the Future
- Conclusion
- Frequently Asked Questions
Why Are Antifungal Drugs Prescribed for Conditions Beyond Fungal Infections?
The answer lies in biochemistry. Ketoconazole works as an antifungal by inhibiting cytochrome P450 14α-demethylase, an enzyme fungi need to build their cell membranes. But ketoconazole is not a precise tool. It also broadly inhibits steroidogenesis enzymes in the human adrenal cortex, specifically 17-alpha-hydroxylase and 17,20-lyase, which are essential for producing cortisol and androgens. This biochemical promiscuity, which would normally be considered a side effect, turned out to be medically useful.
Physicians realized that if a patient’s body was producing dangerously high levels of cortisol, as happens in Cushing’s syndrome, ketoconazole could throttle that production. Itraconazole’s off-label story is different. Rather than interfering with hormone production, itraconazole inhibits angiogenesis, the process by which tumors recruit new blood vessels, and blocks the Hedgehog signaling pathway, a cellular communication system that drives growth in several cancer types. These are not minor laboratory curiosities. Clinical trials have explored itraconazole’s benefits in prostate cancer, basal cell carcinoma, non-small cell lung cancer, ovarian cancer, triple-negative breast cancer, pancreatic cancer, and biliary tract cancer. The distinction matters: ketoconazole found its second life through an accidental side effect, while itraconazole is being deliberately studied through formal drug repurposing research.
Ketoconazole and Cushing’s Syndrome — What the Evidence Shows
Cushing’s syndrome occurs when the body is exposed to high levels of cortisol for an extended period, leading to weight gain, muscle weakness, thinning skin, and cognitive difficulties that can mimic or accelerate dementia-like symptoms. The standard first-line treatment is transsphenoidal surgery to remove the pituitary tumor driving excess cortisol production, but surgery is not always successful or appropriate. This is where ketoconazole enters the picture. Approximately 60 percent of patients with Cushing’s syndrome achieve cortisol control with ketoconazole, with response rates ranging from 45 to 88 percent across key studies. However, ketoconazole carries real risks that limit its use. The drug is well known for hepatotoxicity, and the U.S.
Food and Drug Administration has issued warnings about serious liver injury. This is one reason it remains off-label in the United States for Cushing’s syndrome rather than receiving formal approval, even though Europe has granted approval for this indication. Patients on ketoconazole for cortisol suppression require regular liver function monitoring. If liver enzymes rise significantly, the drug must be discontinued. For older adults, particularly those already managing multiple medications, the drug interaction profile of ketoconazole is another concern. It is a potent inhibitor of CYP3A4, meaning it can dangerously increase blood levels of many commonly prescribed drugs, including certain statins, blood thinners, and sedatives.
Itraconazole’s Emerging Role in Cancer Treatment
Drug repurposing has become an increasingly attractive strategy in oncology because developing a new cancer drug from scratch takes over a decade and billions of dollars, while repurposed drugs already have established safety profiles and manufacturing pipelines. Itraconazole fits this model well. Its ability to inhibit the Hedgehog signaling pathway is particularly relevant because aberrant Hedgehog activity drives tumor growth in basal cell carcinoma, the most common form of skin cancer. Itraconazole has been observed to slow the growth of basal cell carcinoma through this mechanism, offering a potential treatment option for patients who cannot undergo surgery or tolerate other therapies.
The January 2025 study in Frontiers in Pharmacology added another layer to this research by demonstrating that itraconazole promotes melanoma cell apoptosis, or programmed cell death, by inhibiting Hedgehog signaling pathway-mediated autophagy. In simpler terms, the drug appears to prevent melanoma cells from recycling their own damaged components, a survival trick cancer cells often use to resist treatment. Clinical benefits have also been suggested in trials involving non-small cell lung cancer, ovarian cancer, triple-negative breast cancer, pancreatic cancer, and biliary tract cancer, both as a standalone treatment and in combination with standard chemotherapy. These results are promising, but most of this evidence comes from early-phase trials and small studies, and itraconazole has not received regulatory approval for any cancer indication.
Comparing Ketoconazole and Itraconazole for Off-Label Use
For anyone trying to understand which antifungal has stronger evidence for non-fungal applications, the comparison is straightforward but nuanced. Ketoconazole has the longer track record and the harder evidence for a specific non-fungal indication. Its use in Cushing’s syndrome is backed by decades of clinical experience, European regulatory approval, and WHO recognition. It is a drug that physicians prescribe with confidence for cortisol suppression, even if the liver risks require careful management. Itraconazole, by contrast, is earlier in its second-career journey. The cancer research is compelling, but it remains largely investigational.
No oncologist is prescribing itraconazole as a first-line cancer treatment. Where itraconazole does have established off-label use is in dermatology. It has been used for inflammatory skin diseases including atopic eczema, seborrheic dermatitis, and psoriasis, particularly when a fungal or yeast contribution is suspected. Studies have also shown dramatic improvement in patients with keloids and hypertrophic scars treated with oral itraconazole, likely through inhibition of fibroblast growth factors and vascular endothelial growth factors. In a study of 18 patients with stage II or III sarcoidosis, itraconazole combined with corticosteroids for three to six months produced a statistically significant reduction in pulmonary infiltration, improved lung diffusion capacity, and reduced symptoms including cough, dyspnea, and chest pain. The tradeoff is that itraconazole’s non-fungal applications are scattered across many conditions without deep evidence in any single one, while ketoconazole’s non-fungal niche is narrow but well-established.
Risks, Drug Interactions, and Why Off-Label Use Demands Caution
Off-label prescribing is legal and common in medicine, but it carries inherent risks that patients and caregivers should understand. When ketoconazole is prescribed at high doses for prostate cancer, exceeding 800 milligrams per day, the side effect profile intensifies considerably. At these doses, ketoconazole competitively binds to androgen receptors, reducing testosterone and dihydrotestosterone activity in prostate cancer cells, but the hepatotoxicity risk climbs as well. Patients at these dosing levels need close medical supervision and frequent blood work. For older adults with cognitive concerns, the drug interaction issue deserves particular attention.
Both ketoconazole and itraconazole are potent inhibitors of cytochrome P450 enzymes, meaning they can amplify the effects of other medications in unpredictable ways. A patient taking a cholinesterase inhibitor for Alzheimer’s disease, a statin for cardiovascular risk, and ketoconazole for Cushing’s syndrome is navigating a complex pharmacological landscape. The risk is not theoretical. Dangerous drug interactions with azole antifungals are well documented, and polypharmacy is already a major concern in dementia care. No one should start or stop these medications without close coordination with their prescribing physician and pharmacist.
Ketoconazole Shampoo and Hair Loss — A Quieter Off-Label Use
Not all off-label applications of ketoconazole involve serious disease. Ketoconazole shampoo, combined with an oral 5α-reductase inhibitor, is used off-label to treat androgenic alopecia, the medical term for male and female pattern hair loss.
The rationale is that ketoconazole may reduce scalp inflammation associated with the miniaturization of hair follicles, while also having mild anti-androgenic effects when applied topically. This is a low-risk application compared to systemic ketoconazole use, but it illustrates how a single drug can have clinical value across dramatically different contexts, from life-threatening endocrine disorders to cosmetic hair concerns.
What Drug Repurposing Means for the Future
The stories of ketoconazole and itraconazole reflect a broader shift in how medicine discovers new treatments. Drug repurposing is gaining traction not just because it saves time and money, but because modern computational tools can now screen thousands of existing drugs against new disease targets faster than ever before. For brain health specifically, the principle is worth watching.
Several existing medications are being evaluated for neuroprotective or anti-inflammatory properties that were never part of their original design. The Hedgehog signaling pathway that itraconazole inhibits, for instance, plays roles in neurodevelopment and neurodegeneration that researchers are only beginning to understand. Whether these antifungal drugs will eventually find formal approval for their off-label uses remains uncertain, but the pattern is clear. Medicine’s existing pharmacy shelves may hold more solutions than we have recognized, and the willingness to look at old drugs through new lenses is already changing patient care in endocrinology, oncology, and dermatology.
Conclusion
Ketoconazole and itraconazole are two antifungal medications whose stories have expanded well beyond their original purpose. Ketoconazole’s ability to suppress cortisol production has made it a recognized treatment for Cushing’s syndrome, approved in Europe and recommended off-label in the United States, with approximately 60 percent of patients achieving cortisol control. Itraconazole’s inhibition of angiogenesis and the Hedgehog signaling pathway has opened doors in cancer research, dermatology, and pulmonary medicine, though most of these applications remain investigational.
For patients and caregivers navigating complex health conditions, the key takeaway is that these drugs have genuine clinical value beyond their antifungal label, but they also carry significant risks, particularly hepatotoxicity and drug interactions. Off-label use should always be guided by a physician who understands the full medication picture, and no one should self-prescribe these drugs based on research headlines alone. The science is real, but so are the side effects.
Frequently Asked Questions
Is ketoconazole FDA-approved for Cushing’s syndrome?
No. Ketoconazole is approved in Europe for Cushing’s syndrome but is used off-label in the United States, where it is recommended as a second-line treatment after transsphenoidal surgery.
Can itraconazole cure cancer?
No. Clinical trials have suggested benefits in several cancer types including prostate cancer, basal cell carcinoma, non-small cell lung cancer, and melanoma, but itraconazole has not received regulatory approval for any cancer indication. It remains investigational for oncology use.
What is the success rate of ketoconazole for controlling cortisol in Cushing’s syndrome?
Approximately 60 percent of patients achieve cortisol control, with response rates ranging from 45 to 88 percent across key clinical studies.
Are there serious risks associated with using ketoconazole off-label?
Yes. Hepatotoxicity is the primary concern, requiring regular liver function monitoring. Ketoconazole is also a potent CYP3A4 inhibitor, meaning it can significantly increase blood levels of many other medications and create dangerous drug interactions.
What cancers has itraconazole been studied for?
Clinical benefits have been suggested for prostate cancer, basal cell carcinoma, non-small cell lung cancer, ovarian cancer, triple-negative breast cancer, pancreatic cancer, biliary tract cancer, and melanoma. A January 2025 study in Frontiers in Pharmacology specifically demonstrated itraconazole’s ability to promote melanoma cell death.
Is ketoconazole shampoo effective for hair loss?
Ketoconazole shampoo is used off-label for androgenic alopecia, typically in combination with an oral 5α-reductase inhibitor. It may help reduce scalp inflammation, though it is considered a supplemental treatment rather than a primary therapy.
